BACKGROUND: NF-kappaB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas. OBJECTIVE: To review the activation and role of NF-kappaB in pathogenesis and as a target for treatment and prevention in carcinoma. METHODS: Evidence from experimental, epidemiological, preclinical studies and clinical trials cited in the literature are reviewed. RESULTS/ CONCLUSION: Cumulative evidence implicates NF-kappaB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-kappaB have demonstrated activity and safety in prevention or therapy. NF-kappaB-activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.
BACKGROUND:NF-kappaB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas. OBJECTIVE: To review the activation and role of NF-kappaB in pathogenesis and as a target for treatment and prevention in carcinoma. METHODS: Evidence from experimental, epidemiological, preclinical studies and clinical trials cited in the literature are reviewed. RESULTS/ CONCLUSION: Cumulative evidence implicates NF-kappaB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-kappaB have demonstrated activity and safety in prevention or therapy. NF-kappaB-activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.
Authors: James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi Journal: J Biol Chem Date: 2002-10-25 Impact factor: 5.157
Authors: Christine H Chung; Joel S Parker; Kim Ely; Jesse Carter; Yajun Yi; Barbara A Murphy; K Kian Ang; Adel K El-Naggar; Adam M Zanation; Anthony J Cmelak; Shawn Levy; Robbert J Slebos; Wendell G Yarbrough Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Kevin S Berman; Udit N Verma; Gwyndolen Harburg; John D Minna; Melanie H Cobb; Richard B Gaynor Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed Journal: Biofactors Date: 2010 May-Jun Impact factor: 6.113
Authors: Anne R Diers; Brian P Dranka; Karina C Ricart; Joo Yeun Oh; Michelle S Johnson; Fen Zhou; Manuel A Pallero; Thomas M Bodenstine; Joanne E Murphy-Ullrich; Danny R Welch; Aimee Landar Journal: Biochem J Date: 2010-08-15 Impact factor: 3.857
Authors: Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531
Authors: R Sean McNally; Beckley K Davis; Casey M Clements; Mary Ann Accavitti-Loper; Tak W Mak; Jenny P-Y Ting Journal: J Biol Chem Date: 2010-11-19 Impact factor: 5.157
Authors: Josephine Kam Tai Dermawan; Katerina Gurova; John Pink; Afshin Dowlati; Sarmishtha De; Goutham Narla; Neelesh Sharma; George R Stark Journal: Mol Cancer Ther Date: 2014-07-15 Impact factor: 6.261
Authors: Jonah Cohen; Zhong Chen; Shi-Long Lu; Xin Ping Yang; Pattatheyil Arun; Reza Ehsanian; Matthew S Brown; Hai Lu; Bin Yan; Oumou Diallo; Xiao-Jing Wang; Carter Van Waes Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701